Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Fortis nets $18M in Series A
November 2016
SHARING OPTIONS:

SAN DIEGO—Fortis Therapeutics concluded September with the close of an $18-million Series A financing led by Avalon Ventures and joined by Bregua Corporation, Lilly Asia Ventures, Osage University Partners and Vivo Capital. The new company is focused on the development of antibody-drug conjugate therapies, and was founded on technology developed by Dr. Bin Liu, a professor at UCSF, and exclusively in-licensed from the university. The receptor Fortis will be targeting is over-expressed in late-stage prostate cancer, and the genes that encode it are part of the chromosome amplification seen in many multiple myeloma patients with poor prognosis.
 
“We have found a target that is not only over-expressed in late-stage prostate cancer but is further up-regulated under selective pressures of androgen deprivation therapy,” said Dr. Marc Nasoff, chief scientific officer of Fortis and COI Pharmaceuticals. “This target could provide a way to attack the ubiquitous problem of androgen therapy resistance in metastatic castrate-resistant prostate cancer.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.